Get the Stockscreener App
63.35
1.06%
-0.68
After Hours:
63.35
Ani Pharmaceuticals Inc stock is traded at $63.35, with a volume of 196.55K.
It is down -1.06% in the last 24 hours and down -2.91% over the past month.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
See More
Previous Close:
$64.03
Open:
$63.52
24h Volume:
196.55K
Relative Volume:
0.55
Market Cap:
$1.37B
Revenue:
$486.82M
Net Income/Loss:
$18.78M
P/E Ratio:
77.26
EPS:
0.82
Net Cash Flow:
$100.45M
1W Performance:
-5.12%
1M Performance:
-2.91%
6M Performance:
+8.03%
1Y Performance:
-3.61%
1-Day Range:
$62.60
$65.06
1-Week Range:
$62.60
$68.18
52-Week Range:
$52.50
$77.00
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Name
Ani Pharmaceuticals Inc
Sector
Phone
(218) 634-3500
Address
210 MAIN STREET WEST, BAUDETTE, MN
Compare ANIP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
63.35 | 1.39B | 486.82M | 18.78M | 100.45M | 0.82 |
|
ZTS
Zoetis Inc
|
145.79 | 66.25B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 42.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.43 | 43.30B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.45 | 19.30B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
128.23 | 13.53B | 2.41B | 305.80M | 492.20M | 2.95 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Initiated | H.C. Wainwright | Buy |
| Mar-14-25 | Initiated | Jefferies | Buy |
| Mar-12-25 | Initiated | JP Morgan | Overweight |
| Dec-11-24 | Initiated | Leerink Partners | Outperform |
| Oct-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-15-24 | Initiated | CapitalOne | Overweight |
| Aug-22-23 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Sep-07-22 | Initiated | H.C. Wainwright | Buy |
| Nov-02-21 | Initiated | Truist | Buy |
| May-07-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| May-10-19 | Downgrade | Raymond James | Strong Buy → Outperform |
| Oct-16-17 | Reiterated | Canaccord Genuity | Buy |
| Jul-31-17 | Initiated | Canaccord Genuity | Buy |
| Feb-22-17 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-23-16 | Initiated | Raymond James | Strong Buy |
| May-24-16 | Downgrade | Standpoint Research | Buy → Hold |
| Nov-13-15 | Initiated | Standpoint Research | Buy |
| Sep-28-15 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-05-15 | Reiterated | Oppenheimer | Outperform |
| Aug-04-15 | Reiterated | ROTH Capital | Neutral |
| Jul-31-15 | Reiterated | Oppenheimer | Outperform |
| Jul-15-15 | Reiterated | ROTH Capital | Neutral |
| Jun-23-15 | Reiterated | Oppenheimer | Outperform |
| May-18-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Reiterated | Oppenheimer | Outperform |
| Apr-10-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-26-15 | Reiterated | ROTH Capital | Buy |
| Feb-18-15 | Reiterated | Oppenheimer | Outperform |
View All
Ani Pharmaceuticals Inc Stock (ANIP) Latest News
How many analysts rate ANI Pharmaceuticals Inc. as a “Buy”Post Market Recommendation For 2025 - jammulinksnews.com
Lacklustre Performance Is Driving ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Low P/S - 富途牛牛
ANI Pharmaceuticals (NASDAQ:ANIP) pulls back 4.3% this week, but still delivers shareholders strong 16% CAGR over 5 years - Yahoo.co
Does ANI Pharmaceuticals Inc. stock perform well during market downturnsEntry Signal Guidance With Proven Results - jammulinksnews.com
ANI Pharmaceuticals to Challenge Court Verdict - The Globe and Mail
Can ANI Pharmaceuticals Inc. Rally Enough to Break EvenTrend Analysis for Safer Trades Gains Popularity - metal.it
Short Covering May Lift ANI Pharmaceuticals Inc. in Near TermSmart Trade Plans With Risk Protection Explained - metal.it
Why ANI Pharmaceuticals Inc. stock attracts strong analyst attentionTriple Digit Return Forecasts - beatles.ru
CG Oncology wins Delaware jury trial against ANI Pharmaceuticals By Investing.com - Investing.com South Africa
CG Oncology wins Delaware jury trial against ANI Pharmaceuticals - Investing.com Australia
Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals - The Manila Times
CG Oncology Secures Major Legal Victory: Court Rules No 5% Royalties on Promising Bladder Cancer Drug - Stock Titan
Published on: 2025-07-29 19:34:49 - metal.it
Is ANI Pharmaceuticals (ANIP) a High-Probability Earnings Beat Candidate in Q2 2025? - AInvest
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Q2 Release - Yahoo Finance
Published on: 2025-07-29 03:23:31 - metal.it
ANI Pharmaceuticals: Classic Case Of Capital Intensive Growth Hampering Value (NASDAQ:ANIP) - Seeking Alpha
What makes ANI Pharmaceuticals Inc. stock price move sharplyHigh-margin investment plays - jammulinksnews.com
How does ANI Pharmaceuticals Inc. compare to its industry peersCapitalize on market shifts before others do - jammulinksnews.com
What are the latest earnings results for ANI Pharmaceuticals Inc.High-performance investment picks - jammulinksnews.com
How does ANI Pharmaceuticals Inc. generate profit in a changing economySkyrocketing returns - jammulinksnews.com
Is ANI Pharmaceuticals Inc. a growth stock or a value stockPhenomenal capital gains - jammulinksnews.com
What is the dividend policy of ANI Pharmaceuticals Inc. stockMaximize your portfolio’s earning potential - jammulinksnews.com
How ANI Pharmaceuticals Inc. stock performs during market volatility200 Percent Profit Outlook - metal.it
What analysts say about ANI Pharmaceuticals Inc. stockFree Trading Strategy Suggestions - PrintWeekIndia
ANI Pharmaceuticals Inc. Stock Analysis and ForecastBreakneck growth rates - PrintWeekIndia
Is ANI Pharmaceuticals Inc. a good long term investmentTurbocharged investment results - PrintWeekIndia
Is ANI Pharmaceuticals Inc. stock a growth or value playDynamic portfolio growth - jammulinksnews.com
ANI Pharmaceuticals stock holds steady as H.C. Wainwright maintains Buy rating - Investing.com Canada
ANI Pharmaceuticals reports outcomes from diabetic macular oedema trial - Yahoo Finance
ANI Pharma stock drops on trial setback (ANIP:NASDAQ) - Seeking Alpha
What drives ANI Pharmaceuticals Inc. stock priceBreakthrough capital growth - jammulinksnews.com
ANI Pharmaceuticals Reports on NEW DAY Clinical Trial Results - TipRanks
ANI Pharmaceuticals reports mixed results from NEW DAY trial for DME - Investing.com Australia
ANI Pharmaceuticals reports mixed results from NEW DAY trial for DME By Investing.com - Investing.com South Africa
ANI Pharmaceuticals Announces Results from NEW DAY Clinical - GlobeNewswire
Clinical Trial Reveals ILUVIEN Cuts DME Treatment Burden: Patients Need Only 2.8 vs 7.5 Injections - Stock Titan
Ani Pharmaceuticals Inc Stock (ANIP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
0.85%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):